What do systematic reviews say?

Bupropion vs placebo

Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).

• Strategies for managing sexual dysfunction induced by antidepressant medication 2013 · Cochrane Headline outcomes only
  RR 1.08 [0.67, 1.72]
  5 studies · 579 participants
  High

QUETIAPINE vs Typical antipsychotics

Quetiapine showed no clear difference in global state No clinical significant response as defined by the… compared with typical antipsychotics (moderate certainty).

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  RR 0.96 [0.75, 1.23]
  16 studies · 1607 participants
  Moderate

QUETIAPINE vs Typical antipsychotics

Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  RR 0.91 [0.81, 1.01]
  23 studies · 3576 participants
  Moderate

QUETIAPINE vs Typical antipsychotics

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 1934 participants
  Moderate

QUETIAPINE vs Typical antipsychotics

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 1934 participants
  Moderate

QUETIAPINE vs Typical antipsychotics

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 142 participants
  Very low

QUETIAPINE vs Typical antipsychotics

Quetiapine probably leads to lower extrapyramidal effects compared with typical antipsychotics (moderate certainty).

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  RR 0.17 [0.09, 0.32]
  8 studies · 1095 participants
  Moderate

QUETIAPINE vs Typical antipsychotics

• Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1034 participants
  Moderate

Formoterol vs short‐acting beta2‐agonist

Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).

• Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
  OR 0.84 [0.67, 1.04]
  7 studies · 22236 participants
  Moderate

Formoterol vs short‐acting beta2‐agonist

Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).

• Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
  OR 0.84 [0.77, 0.91]
  6 studies · 21591 participants
  Moderate

Formoterol vs short‐acting beta2‐agonist

Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).

• Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
  OR 1.08 [0.51, 2.3]
  5 studies · 21629 participants
  Low

Formoterol vs short‐acting beta2‐agonist

Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).

• Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
  OR 0.94 [0.81, 1.08]
  7 studies · 22538 participants
  Low

Formoterol vs short‐acting beta2‐agonist

Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).

• Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
  OR 0.91 [0.72, 1.15]
  6 studies · 21986 participants
  Low

Formoterol vs short‐acting beta2‐agonist

Formoterol may leads to higher withdrawals (any reason) compared with short‐acting beta2‐agonist (low certainty).

• Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
  OR 1.12 [1.02, 1.24]
  7 studies · 22541 participants
  Low

CLOZAPINE vs Typical antipsychotics

CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).

• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 0.62 [0.45, 0.84]
  19 studies · 1303 participants
  Moderate
• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 0.22 [0.14, 0.34]
  4 studies · 578 participants
  Moderate
• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 1.04 [0.61, 1.78]
  4 studies · 396 participants
  Moderate

CLOZAPINE vs Typical antipsychotics

CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).

• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 0.71 [0.64, 0.79]
  4 studies · 370 participants
  Moderate
• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 0.83 [0.76, 0.91]
  2 studies · 648 participants
  Moderate
• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 0.72 [0.66, 0.79]
  14 studies · 1119 participants
  Moderate

CLOZAPINE vs Typical antipsychotics

CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.

• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 1.9 [0.97, 3.71]
  5 studies · 827 participants
  GRADE not reported

CLOZAPINE vs Typical antipsychotics

CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).

• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 2.01 [1.74, 2.32]
  5 studies · 827 participants
  Moderate
• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 2.25 [1.96, 2.58]
  17 studies · 1479 participants
  Moderate

CLOZAPINE vs Typical antipsychotics

CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).

• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 1.33 [1.11, 1.59]
  3 studies · 484 participants
  Moderate
• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 1.28 [1.07, 1.53]
  5 studies · 590 participants
  Moderate

CLOZAPINE vs Typical antipsychotics

CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).

• Clozapine versus typical neuroleptic medication for schizophrenia 2009 · Cochrane Headline outcomes only
  RR 0.87 [0.75, 1]
  4 studies · 416 participants
  Moderate